AzTrials
AzTrials

Infection, HospitalGer-SPNCT05475574

Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit

A study testing Discontinuation of contact precautions for ESBLE in people with Infection, Hospital, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study. The aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase… Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Infection, Hospital
What is being tested?
Discontinuation of contact precautions for ESBLE
Could I receive a placebo?
No, everyone receives an active treatment
How many people
954 participants
Where
1 siteFrance
Study dates
7 Mar 2023to 21 Sep 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Adult patient (> 65 years old)
  • Patient hospitalized in geriatrics during the study period
  • Free and informed consent obtained from the patient (or his trusted person or legal representative) within 48 hours of its admission at the geriatric unit
  • Patient affiliated to a social security scheme
  • Non Inclusion Criteria:
  • Patient requiring contact precaution for an indication other than ESBLE (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC) on admission
  • Patient under legal protection
  • Person deprived of liberty

Who cannot join

  • Patient requiring contact precaution for an indication other than ESBL during the patient stay (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC)
  • Patient's stay period less than 4 days

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • CHR Metz-Thionville/Hôpital Bel Air

    Metz, 57085

    Azzedine AZZEMOU, MD, a.azzemou@chr-metz-thionville.fr

    Recruiting

Other trials in France

About this study

Official title: Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae (ESBLE) in a Geriatric Unit: an Interventional Prospective Noninferiority Non-randomized Double-blind Controlled Before and After Study

This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study.

The aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae acquired in geriatric units before and after discontinuing contact precautions.

Read the detailed description

Healthcare-associated infections (HAIs) are one of the main causes of morbidity and mortality worldwide. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae have become microorganisms frequently found in HAIs, which reduces the therapeutic possibilities.

Being tested
Discontinuation of contact precautions for ESBLE
Medical subject headings
Cross Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Discontinuation of contact precautions for ESBLEOther

    Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE

Study groups in NCT05475574
Study groupRoleWhat they receive
Before discontinuation of contact precautions for ESBLENo interventionImplementation of contact precaution in addition to standard precaution for any patient carrying (infected or colonized) ESBLE
After discontinuation of contact precautions for ESBLEExperimentalDiscontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
Receives: Other: Discontinuation of contact precautions for ESBLE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence density of acquired ESBLE

    Incidence density of acquired ESBLE in geriatric unit for 1000 days of hospitalization is calculated by dividing the number of acquired ESBLE by the number of days of patients' hospitalization multiplied by 1000 Acquisition of ESBLE is defined by a positive sample in patient on discharge day with a negative sample on admission in geriatric unit A positive sample is defined by the presence of at least one ESBLE on a clinical (infection) or screening (colonization) sample.

    The hospitalisation number is calculated as the cumulative length of stay of all patients at risk (= negative on admission).

    Measured: during 6 month period

Secondary outcomes (5)
  1. Incidence density of acquired ESBLE by species during 6 month period

    Incidence density of acquired ESBLE in geriatric unit by species (E. coli versus non-E. coli) for 1000 days of hospitalization. This is calculated by dividing the number of acquired ESBLE by species by the number of days of patients' hospitalization multiplied by 1000.

    Acquisition of ESBLE is defined by a positive sample in patient on discharge day with a negative sample on admission in geriatric unit A positive sample is defined by the presence of at least one ESBLE on a clinical (infection) or screening (colonization) sample.

    The hospitalisation number is calculated as the cumulative length of stay of all patients at risk (= negative on admission).

    Measured: during 6 month period

  2. The rate of compliance with hand hygiene in health care providers

    The evaluation of the compliance with hygiene measures is calculated in health care providers by dividing the number of hand hygiene moments carried out by the number of opportunities multiplied by 100, according to the World Health Organization (WHO) methodology

    Measured: Up to 3 months per health department

  3. Evaluation of the barriers to alcohol-based hand rub in case of non-compliance in health care providers

    The barriers to alcohol-based hand rub are identified in case of non-compliance, using a Pulpe' friction questionnaire (RéPIAS) where professionals are interviewed about their practices in terms of hand hygiene. For each situation, the professional is also asked how important it is for him to perform hand hygiene in each situation listed above, with a slider to be positioned between 0 (not at all important; worse outcome) and 10 (the most important; better outcome).

    Measured: Up to 3 months per health department

  4. The rate of compliance with personal protective equipment

    The rate of compliance with the wearing and removal of personal protective equipment throughout patient care, is observed during care related to the management of excreta (changing, putting on or removing a dish basin, use of a basin washer-disinfector).

    The rate is calculated by dividing the number of personal protective equipment good caring practices by the number of opportunities multiplied by 100.

    Measured: Up to 3 months per health department

  5. Evaluation of satisfaction related to patient care, by self-questionnaire Hospital anxiety and depression scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item measure designed to assess anxiety and depression symptoms in medical patients, with emphasis on reducing the impact of physical illness on the total score.

    Items are rated on a 4-point severity scale. The HADS produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states. Scores of greater than or equal to 11 on either scale indicate a definitive case.

    Measured: on the day of discharge of the geriatric unit, on average on the 11th day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2022
  2. Study start7 Mar 2023
  3. Primary completion7 Sep 2029 (estimated)
  4. Study completion21 Sep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
954 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05475574
Sponsor's protocol ID
2021-05-CHRMT
Acronym
Ger-SP
Status last verified
Jun 2026
First submitted
13 Jul 2022
Last updated
24 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Discontinuation of contact precautions for ESBLE in people with Infection, Hospital, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Laurie RENAUDIN, MD (03 87 55 30 25 ext. 0033, l.renaudin@chr-metz-thionville.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence density of acquired ESBLE (time frame: during 6 month period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in